--- title: "iBio (IBIO) news: delisting, offering and Nasdaq notice" url: "https://aibio.space/companies/ibio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IBIO delisting, offering and Nasdaq notice news: iBio files Form 25 to withdraw its common stock from NYSE American. iBio, Inc." --- IBIO iBio, Inc. NASDAQ · United States # iBio (IBIO) news IBIO delisting, offering and Nasdaq notice news Financings · 2026-01-09 ## [iBio raises $26 million from Frazier-led investors to push obesity antibodies toward clinic](https://aibio.space/news/ibio-raises-26-million-frazier-led-investors-push-obesity-antibodies/) The AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027. ## Latest iBio news 1. 2025-08-01 Listings [iBio receives Nasdaq notice for trading below $1.00 minimum bid price](https://aibio.space/news/ibio-receives-nasdaq-notice-trading-below-1-00-minimum-bid-price/) The company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now. 2. 2025-03-03 Listings [iBio files Form 25 to withdraw its common stock from NYSE American](https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/) The company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so. 3. 2025-01-13 Financings [iBio sells 240,807 shares to officers and directors in $655,000 private placement](https://aibio.space/news/ibio-sells-240-807-shares-officers-directors-655-000-private-placement/) iBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market. 4. 2025-01-02 Financings [iBio in-licenses anti-myostatin antibody from AstralBio, paying $750,000 upfront in stock](https://aibio.space/news/ibio-licenses-anti-myostatin-antibody-astralbio-paying-750-000-upfront/) iBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical. ## iBio at a glance - **Ticker**: IBIO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $88.0 million ### Related companies - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) NASDAQ: RNAZ - [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST - [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) NASDAQ: DFTX - [PharmaCyte Biotech](https://aibio.space/companies/pharmacyte-biotech/) NASDAQ: PMCB - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) NASDAQ: CURX - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB - [Scilex Holding](https://aibio.space/companies/scilex/) NASDAQ: SCLX ### Also on NASDAQ - [Pasithea Therapeutics](https://aibio.space/companies/pasithea-therapeutics/) KTTA - [BIOLIFE SOLUTIONS INC](https://aibio.space/companies/biolife-solutions/) BLFS - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) ARWR - [INSULET CORP](https://aibio.space/companies/insulet/) PODD - [BioNTech](https://aibio.space/companies/biontech/) BNTX - [Rallybio](https://aibio.space/companies/rallybio/) RLYB ## What iBio does iBio is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to develop hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. The company is focused on the quality, durability and tolerability of weight loss, including preserving muscle mass, compared with current GLP-1 receptor agonist therapies. The first molecule from its AI Drug Discovery Platform to enter clinical development, IBIO-600, a long-acting myostatin antibody, has a Phase 1 trial in Australia, where the first participant was dosed in June 2026. The company reports that 31 participants have been dosed across the first four cohorts. IBIO-610, a long-acting Activin E antibody, is in IND-enabling studies, with first-in-human trials anticipated in the first half of calendar year 2027. IBIO-800, a myostatin and Activin A bispecific antibody, is in IND-enabling development for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). On August 27, 2026, the company entered into an exclusive worldwide license with AstralBio for an amylin program. | Product or program | What it is | Stage | |---|---|---| | IBIO-600 | Long-acting myostatin antibody for obesity | Phase 1 in Australia; first participant dosed June 2026 | | IBIO-610 | Long-acting Activin E antibody for obesity | IND-enabling studies; first-in-human trials expected in the first half of calendar year 2027 | | IBIO-800 | Myostatin and Activin A bispecific antibody for PH-HFpEF | IND-enabling development | Summarised from the company's [10-K filed Aug 28, 2026](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm). ## iBio annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$19.6 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | [$8.3 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | | Net income (loss) | [-$33.0 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | [-$18.4 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | | Cash from operations | [-$23.2 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | [-$15.3 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | | Cash and equivalents | [$56.4 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | | Short-term investments | [$31.6 million](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/) | [$0](https://www.sec.gov/Archives/edgar/data/1420720/000110465926059416/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $56.4 million, plus short-term investments of $31.6 million, $88.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about iBio Was iBio delisted? Our latest story on this, dated Mar 3, 2025: "iBio files Form 25 to withdraw its common stock from NYSE American". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/). Has iBio raised money recently? Our latest story on this, dated Jan 9, 2026: "iBio raises $26 million from Frazier-led investors to push obesity antibodies toward clinic". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ibio-raises-26-million-frazier-led-investors-push-obesity-antibodies/). Has iBio received a Nasdaq deficiency notice? Our latest story on this, dated Aug 1, 2025: "iBio receives Nasdaq notice for trading below $1.00 minimum bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ibio-receives-nasdaq-notice-trading-below-1-00-minimum-bid-price/). What is the ticker symbol of iBio? iBio, Inc. trades under the ticker IBIO on NASDAQ. Where is iBio listed? iBio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0JV0. What is the SEC CIK of iBio? The SEC Central Index Key (CIK) for iBio, Inc. is 1420720. Its filings are on SEC EDGAR. How many shares does iBio have outstanding? 64,307,256 shares as of 2026-08-27, per the cover page of its 10-K filed 2026-08-28. Which country or territory is iBio listed under? Our directory records iBio, Inc. under United States. What does iBio do? Our directory classifies iBio, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of iBio? The ISIN recorded for iBio, Inc. is US4510337086. Does aibio.space cover iBio? aibio.space lists iBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is iBio incorporated? SEC records list its state or country of incorporation as DE. What does iBio develop? iBio is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to develop hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. The company is focused on the quality, durability and tolerability of weight loss, including preserving muscle mass, compared with current GLP-1 receptor agonist therapies. What is IBIO-600 from iBio? IBIO-600: Long-acting myostatin antibody for obesity Stage: Phase 1 in Australia; first participant dosed June 2026. What is IBIO-610 from iBio? IBIO-610: Long-acting Activin E antibody for obesity Stage: IND-enabling studies; first-in-human trials expected in the first half of calendar year 2027. ## Investor discussion: iBio Members talk about iBio (IBIO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at iBio, newest first. Each line links the filing it comes from. 1. 2026-10-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000032/ibio-20261014x8k.htm) 2. 2026-08-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722xex99d1.htm) 3. 2026-02-27 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1420720/000110465926021610/tm267370d1_s3.htm) 4. 2026-01-30 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1420720/000110465926008643/tm264215d1_s3.htm) 5. 2026-01-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/tm262944d1_ex99-1.htm) 6. 2025-11-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000142072025000035/ibio-20251104x8k.htm) 7. 2025-08-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000155837025009992/ibio-20250729x8k.htm) 8. 2025-03-03 Listings Filed to remove its shares from exchange listing. SEC Form 25. [Source](https://www.sec.gov/Archives/edgar/data/1420720/000110465925019785/tm257812d2_25.htm) 9. 2025-02-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000142072025000014/ibio-20250219xex99d1.htm) 10. 2025-01-31 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1420720/000110465925008187/tm254943d1_s3.htm) 11. 2025-01-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/ibio-20241230xex99d1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IBIO on TradingView](https://www.tradingview.com/symbols/NASDAQ-IBIO/). ## SEC filings and registration - **SEC name**: iBio, Inc. - **CIK**: 1420720 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IBIO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737 - **Phone**: 302 355-0650 - **Shares outstanding**: 64,307,256 as of 2026-08-27 (10-K filed 2026-08-28) - **Former names**: iBio, Inc.; iBioPharma, Inc.; InB:Biotechnologies, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000032/ibio-20261014x8k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/ibio-20261013x8k.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000028/ibio-20260914x8k.htm) filed 2026-09-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000022/ibio-20260904xdef14a.htm) filed 2026-09-04 - [10-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/ibio-20260731x10k.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828x8k.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722x8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000012/ibio-20260717x8k.htm) filed 2026-07-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001420720), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details iBio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IBIO, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: iBio, Inc. - **Ticker**: IBIO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US4510337086 - **Other listed symbols**: GETTEX:0JV0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IBIO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ibio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "iBio (IBIO) news: delisting, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/ibio/